Would you consider transitioning patients older than 75 years of age with coronary disease from statins and/or other lipid-lowering agents to PCSK9 inhibitors given concerns for polypharmacy, provided their LDL levels remain at or below goal?  

I don't view or use age as a specific guide, per se. Overall, currently, we have several excellent choices available for LDLc reduction. We must work with our patients in developing the best approaches to lowering their LDL-C to reduce cardiovascular events. Side effects, tolerability, cost, and pre...

We do not have any data to suggest PCSK9i are better than statins, and all of the PCSK9i outcomes data are on top of statins. Data show generally that lower is better, and there isn’t a “floor” to benefit. That said, if I have someone on statin + ezetimibe who then gets LDL-C very ...